Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Gimme Care vs PlexusDx

Gimme Care
Graded #23

Higher grade

vs+16.89999999999999
PlexusDx
Graded #158

Lower grade

The verdict

Gimme Care takes it — 84.6/100 to 67.7/100.

Gimme Care grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-value both-molecule pricing ($130/$163), verified, and nationwide.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGimme Care +15
89
74
Dose & formulationGimme Care +16
80
64
Clinical oversightGimme Care +10
84
74
Labs & monitoringGimme Care +30
82
52
FulfillmentGimme Care +9
87
78
Contract termsGimme Care +30
85
55
Gimme Care · left barPlexusDx · right bar

The numbers

MetricGimme CarePlexusDx
WeighScore84.6/10067.7/100
GradeBC
Scorecard rank#23#158
Semaglutide$130/mo$149/mo (starting dose, compounded)
Tirzepatide$163/mo$249/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Gimme Care

Graded #23 · B

Strengths

  • $130 sema / $163 tirz
  • All 50 states, LegitScript-verified
  • Both molecules

Where it loses points

  • Not the cheapest tier
  • Injection-only
  • Monitoring detail limited
PlexusDx

Graded #158 · C

Strengths

  • Licensed providers available in all 50 states
  • Range of options including low-cost microdose GLP-1 from $129/mo
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

Where it loses points

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • Tirzepatide pricing from $249/mo is higher than budget rivals
  • No insurance accepted

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard